In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Study reports novel findings in prediction of sudden death after myocardial infarction

Cardiac Magnetic Resonance

Barcelona, Spain – 29 Aug 2022: Clinical data and cardiac magnetic resonance (CMR) imaging did not improve risk prediction for sudden cardiac death (SCD) after myocardial infarction in the largest pooled patient cohort collected to date. The late breaking research from the PROFID project is presented at ESC Congress 2022.1

SCD is responsible for approximately one in five fatalities and is usually due to myocardial infarction. A prophylactic implantable cardioverter defibrillator (ICD) is recommended for patients with an ejection fraction of 35% or lower,2 but most SCDs occur in those with an ejection fraction above 35%. Many patients who might benefit from an ICD are not eligible, and very few patients who qualify for an ICD will ever need it.

PROFID aimed to develop a prediction model for the risk of SCD after myocardial infarction to select patients for prophylactic ICDs. Today the researchers reported the limited value of currently available risk stratification parameters for the prediction of the individual risk of SCD in post-infarction patients, corrected for the competing risk of dying from other causes. The researchers analysed patients with 1) previous myocardial infarction regardless of ejection fraction and 2) ischaemic cardiomyopathy with ejection fraction below 50%.

In the first phase of the analysis, 19 datasets from Europe, Israel and the US containing demographics, clinical parameters, medication, electrocardiogram variables, biomarkers and echocardiographic parameters, including left ventricular ejection fraction (LVEF), were analysed. The second phase consisted of analysis of seven datasets from Europe and the US that incorporated CMR measures obtained at least 40 days after myocardial infarction. Measurements derived from CMR included LVEF, size of infarct scar, which is the area of dead heart muscle after a myocardial infarction, and size of the grey zone, which is the border between the infarcted scar area and healthy myocardium. The primary outcome was SCD in patients without an ICD, or first appropriate ICD therapy as a surrogate for SCD in ICD carriers.

The phase one analysis included both patients with and without an ICD. In the 8,403 ICD patients (85% men, average age 64 years, average LVEF 26.5%), a total of 1,481 primary outcomes were observed during an average follow up of 31 months. Using LVEF as the sole and continuous predictor, which is the current standard, had on average a poor predictive performance for SCD. In the 120,445 non-ICD patients (68% men, average age 68 years), a total of 1,801 primary outcomes occurred during an average follow up of 58.4 months. Using LVEF as the sole and continuous predictor for SCD had on average a moderate performance with an area under curve for SCD risk at 12 months of 0.614.

The phase two analysis included 2,156 patients with an average age of 64 years and average LVEF of 36.8%. A total of 149 primary outcomes occurred during a median follow up of 36 months. This analysis showed that inclusion of CMR parameters, in particular extent of scar and of grey zone, did not substantially improve the predictive performance.

Study author Dr. Nikolaos Dagres of the Heart Center Leipzig, Germany said: “The results of our analysis show that LVEF is only a moderate predictor of sudden cardiac death in patients after myocardial infarction and that other parameters including previously reported candidate predictors, clinical data and CMR measurements did not increase the predictive performance. We also found that overall, the risk for sudden cardiac death is low in patients with LVEF 35% or below and very low in patients with LVEF above 35%.”

In the next step, these findings will inform the design of the randomised PROFID trial programme so that a contemporary approach to selection of patients for prophylactic ICD therapy can be developed.



Notes to editor

ESC Press Office
Tel: +33 (0) 7 8531 2036

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2022 is #ESCCongress.


Funding: PROFID has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847999.


Disclosures: Nikolaos Dagres, Niels Peek, Artur Akbarov, David Jenkins, Zoher Kapacee, Alireza-Sepehri-Shamloo, Glen Martin, Gerhard Hindricks - nothing to disclose.


References and notes

1The final results of the PROFID analysis will be presented during the session Latest science in arrhythmias on Monday 29 August at 11:15 to 12:15 CEST in the Picasso room.

2Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015;36:2793–2867.


About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2022

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online – from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at